Polska - polski - Ministerstwo Rolnictwa i Rozwoju Wsi

natural plant protection route d'artix b.p. , 80-64150 nogures, francja - cydia pomonella granulosis virus - 909 g - insektycyd

Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

ranbaxy (poland) sp. z o.o. - entecavirum - tabletki powlekane - 0,5 mg

Polska - polski - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

ranbaxy (poland) sp. z o.o. - entecavirum - tabletki powlekane - 1 mg

Unia Europejska - polski - EMA (European Medicines Agency)

laboratorios hipra s.a. - żywa аттенуированная wirus rsv bydła (brsv), odcedzić Лым-56 - immunomodulatorów dla byka, bydło, żywe szczepionki wirusowe, uparty wirus rsv (brsv) - bydło - aktywnej immunizacji bydła, aby zmniejszyć wydzielanie wirusa i układu oddechowego objawów klinicznych spowodowanych przez wirus syncytial wirusowa bydła .

Unia Europejska - polski - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinowany wirus везикулярного zapalenie jamy ustnej (szczep warmińsko-mazurskie) z usuwanie kopercie glikoproteiny, zastąpione ebola zair (szczep киквите 1995) glikoproteiny powierzchniowe - gorączka krwotoczna ebola - szczepionki - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. korzystanie z ervebo powinny być zgodne z oficjalnymi zaleceniami.

Unia Europejska - polski - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - gorączka krwotoczna ebola - szczepionki - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unia Europejska - polski - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - gorączka krwotoczna ebola - szczepionki - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Unia Europejska - polski - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - immunologiczne dla aves - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Unia Europejska - polski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - wieprzowy - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Unia Europejska - polski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - immunologiczne dla aves - kurczak - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).